Openshaw, M. R. http://orcid.org/0000-0001-6973-3067
Gervasi, E.
Fulgenzi, C. A. M.
Pinato, D. J.
Dalla Pria, A.
Bower, M.
Article History
Received: 8 February 2023
Accepted: 12 April 2023
First Online: 27 April 2023
Declarations
:
: Retrospective data collection was approved by the national centre for HIV malignancy. No Patient identifiable information was collected.
: This is not a case report and contains no patient identifiable information. All listed authors consent to publication of this final manuscript.
: David J Pinato received lecture fees from ViiV Healthcare, Bayer Healthcare, BMS, Roche, EISAI, Falk Foundation, travel expenses from BMS and Bayer Healthcare; consulting fees for Mina Therapeutics, EISAI, Roche, DaVolterra and Astra Zeneca; research funding (to institution) from MSD and BMS. Mark R Openshaw received travel expenses from Servier. No other conflicts of interest.